EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Factors influencing the cost-effectiveness of radiofrequency ablation for Barrett’s esophagus with low-grade dysplasia in Australia

Lauren Caush, Jody Church iD, Stephen Goodall, Reginald V Lord

Diseases of the Esophagus · 2025

DOI: 10.1093/dote/doae095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diseases of the Esophagus, 2025. Verfasst von Lauren Caush und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The University of Notre Dame School of Medicine, Sydney, Australia. Hauptthemen laut MEDLINE: Barrett Esophagus, Cost-Benefit Analysis, Quality-Adjusted Life Years, Radiofrequency Ablation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endoscopic eradication therapy using radiofrequency ablation (RFA) is considered an acceptable alternative to surveillance monitoring for Barrett’s esophagus with low-grade dysplasia (LGD). This study aimed to estimate whether RFA for LGD is cost-effective and to determine which factors influence cost-effectiveness. A Markov model was developed to estimate the incremental cost per quality-adjusted life year (QALY) gained for RFA compared with endoscopic surveillance. An Australian longitudinal cohort study (PROBE-NET) provides the basis of the model. Replacing surveillance with RFA yields 10 fewer cases of HGD and 9 fewer esophageal adenocarcinoma (EAC)-related deaths per 1000 patients’ treatment, given on average 0.192 QALYs at an additional cost of AU$9211 (€5689; US$6262) per patient (incremental cost-effectiveness ratio AU$47,815 per QALY). The model is sensitive to the rate of EAC from LGD health state, the utility values, and the number of RFA sessions. Hence, the incremental benefit ranges from 0.080 QALYs to 0.198 QALYs leading to uncertainty in the cost-effectiveness estimates. When the cancerous progression rate of LGD falls <0.47% per annum, the cost-effectiveness of RFA becomes questionable. RFA treatment of LGD provides significantly better clinical outcomes than surveillance. The additional cost of RFA is acceptable if the LGD to EAC rate is >0.47% per annum and no more than three RFA treatment sessions are provided. Accurate estimates of the risk of developing EAC in patients with LGD are needed to validate the analyses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Barrett EsophagusCost-Benefit AnalysisQuality-Adjusted Life YearsRadiofrequency AblationMarkov ChainsEsophageal NeoplasmsAdenocarcinomaHumansAustraliaLongitudinal StudiesEsophagoscopyMaleFemaleMiddle AgedAgedDisease Progression

Stichwörter der Autor:innen

Barrett’s esophaguscost-effectivenesseconomic evaluationesophageal adenocarcinomaradiofrequency ablation

Autor:innen und Institutionen

  • Department of Surgery, The University of Notre Dame School of Medicine, Sydney, Australia.
  • Faculty of Health, Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, Australia.
  • Gastroesophageal Cancer Research Program, St. Vincent's Centre for Applied Medical Research, Sydney, Australia.

ORCID-Profile: Jody Church

Zitieren

APA

Caush, L., Church, J., Goodall, S., & Lord, R. V. (2025). Factors influencing the cost-effectiveness of radiofrequency ablation for Barrett’s esophagus with low-grade dysplasia in Australia. Diseases of the Esophagus. https://doi.org/10.1093/dote/doae095

Vancouver

Caush L, Church J, Goodall S, Lord RV. Factors influencing the cost-effectiveness of radiofrequency ablation for Barrett’s esophagus with low-grade dysplasia in Australia. Diseases of the Esophagus. 2025. doi:10.1093/dote/doae095

BibTeX
@article{Caush2025,
  author = {Caush, Lauren and Church, Jody and Goodall, Stephen and Lord, Reginald V},
  title = {Factors influencing the cost-effectiveness of radiofrequency ablation for Barrett’s esophagus with low-grade dysplasia in Australia},
  journal = {Diseases of the Esophagus},
  year = {2025},
  doi = {10.1093/dote/doae095}
}
Kostenlos starten →